Abstract
Aim:
This retrospective analysis investigated the effectiveness of combination therapy with bevacizumab and chemotherapy in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer.
Patients & methods:
Patients with KRAS wild-type metastatic colorectal cancer in the CORECT registry who initiated treatment with bevacizumab between 2008 and 2012 were enrolled. Overall survival and progression-free survival were the main effectiveness end points.
Results:
A total of 981 patients were enrolled. Median progression-free survival was 11.3 months (95% CI: 10.7-11.8) and median overall survival was 28.4 months (95% CI: 26.2-30.6). The most common adverse events were thromboembolic disease (4%) and hypertension (3.5%).
Conclusion:
This retrospective analysis shows the effectiveness of bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer.
Keywords:
KRAS; bevacizumab; chemotherapy; colorectal cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / genetics
-
Colorectal Neoplasms / mortality
-
Colorectal Neoplasms / pathology
-
Disease-Free Survival
-
Fluorouracil / therapeutic use
-
Humans
-
Kaplan-Meier Estimate
-
Leucovorin / therapeutic use
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / genetics
-
Liver Neoplasms / mortality
-
Liver Neoplasms / secondary
-
Lymphatic Metastasis
-
Middle Aged
-
Organoplatinum Compounds / therapeutic use
-
Proto-Oncogene Proteins / genetics
-
Proto-Oncogene Proteins p21(ras)
-
Young Adult
-
ras Proteins / genetics
Substances
-
Antibodies, Monoclonal, Humanized
-
KRAS protein, human
-
Organoplatinum Compounds
-
Proto-Oncogene Proteins
-
Bevacizumab
-
Proto-Oncogene Proteins p21(ras)
-
ras Proteins
-
Leucovorin
-
Fluorouracil